董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James W. Bullock | 男 | Independent Director | 69 | 24.75万美元 | 6.86 | 2026-03-31 |
| Marna P. Borgstrom | 女 | Independent Director | 72 | 25.00万美元 | 4.91 | 2026-03-31 |
| Elizabeth A. Hoff | -- | Independent Director | -- | 24.50万美元 | 2.72 | 2026-03-31 |
| Anthony B. Semedo | -- | Independent Director | -- | 24.75万美元 | 4.00 | 2026-03-31 |
| Jeffrey H. Burbank | 男 | Lead Independent Director | 63 | 29.50万美元 | 5.38 | 2026-03-31 |
| Daniel J. Bevevino | 男 | Independent Director | 67 | 26.50万美元 | 15.01 | 2026-03-31 |
| James P. Mackin | 男 | President, Chief Executive Officer and Chairman of the Board | 59 | 688.31万美元 | 141.75 | 2026-03-31 |
| Thomas F. Ackerman | 男 | Independent Director | 71 | 26.00万美元 | 14.99 | 2026-03-31 |
| Jon W. Salveson | 男 | Independent Director | 61 | 24.50万美元 | 12.98 | 2026-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John E. Davis | 男 | Senior Vice President, Global Sales and Marketing | 61 | 195.80万美元 | 29.64 | 2026-03-31 |
| Amy D. Horton | 女 | Vice President and Chief Accounting Officer | 55 | 未披露 | 未持股 | 2026-03-31 |
| Lance A. Berry | 男 | Chief Operating Officer, Chief Financial Officer and Treasurer | 54 | 297.71万美元 | 23.00 | 2026-03-31 |
| Matthew A. Getz | 男 | Vice President, Human Resources | 57 | 未披露 | 未持股 | 2026-03-31 |
| Rochelle L. Maney | 女 | Vice President, Global Quality | 49 | 未披露 | 未持股 | 2026-03-31 |
| Florian Tyrs | 男 | Vice President, Global Operations | 44 | 未披露 | 未持股 | 2026-03-31 |
| Andrew M. Green | 男 | Vice President, Regulatory Affairs | 57 | 未披露 | 未持股 | 2026-03-31 |
| Robert C. Thon | 男 | Vice President, Research and Development | 56 | 未披露 | 未持股 | 2026-03-31 |
| James P. Mackin | 男 | President, Chief Executive Officer and Chairman of the Board | 59 | 688.31万美元 | 141.75 | 2026-03-31 |
| Jean F. Holloway | 女 | Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | 68 | 190.96万美元 | 23.44 | 2026-03-31 |
董事简历
中英对照 | 中文 | 英文- James W. Bullock
-
JamesW.Bullock自2016年10月起担任CryoLife的董事。Bullock先生是Zyga Technology，Inc.的总裁兼首席执行官，该公司是一家私人控股的医疗设备公司，专注于治疗腰椎疾病的产品。他也担任Split Rock Partners LLC（风险投资公司，投资于医疗设备领域，专注于治疗设备）的常驻执行官。他自2011年以来担任这两个职位。此前，他曾担任Atritech，Inc.的总裁兼首席执行官6年。Atritech是一家私人持有的心血管制造公司，被Boston Scientific NYSE:BSX收购。在此之前，他在EndCardial Solutions，Inc.（纳斯达克市场代码:ECSI）担任了9年的总裁兼首席执行官，该公司是一家专注于心脏的医疗设备公司，被St.Jude Medical收购，后者被雅培公司（纽约证券交易所市场代码:ABT）收购。他还在Stuart Medical，Inc.担任该职位，并在Stackhouse，Inc.，Baxter梦百合，Inc.（NYSE:BAX）和American Hospital Supply Corporation担任多个销售领导职位。Bullock先生曾在七家私人公司和一家上市公司的董事会任职。目前，除了CryoLife的董事会，Bullock先生还担任Stimdia的董事会主席，该公司是Andarta Medical的一家私人控股的初创子公司，Inc.，该公司正在进行研究，以开发用于呼吸机引起的膈肌功能障碍的重症监护治疗的医疗器械。Bullock先生在亚利桑那大学（University of Arizona）获得公共管理学士学位。
James W. Bullock has served as a director of CryoLife since October 2016. Mr. Bullock previously served as the President and Chief Executive Officer of Zyga Technology, Inc. "Zyga Technology", a privately-held medical device company focused on products that treat conditions of the lumbar spine, until January 2018 when RTI Surgical, Inc. (formerly NASDAQ: RTIX) acquired Zyga Technology. Prior to that, he served for six years as President and Chief Executive Officer of Atritech, Inc. Atritech was a privately-held cardiovascular manufacturing company that was acquired by Boston Scientific Corporation (NYSE: BSX). Prior to that, he served for nine years as President and Chief Executive Officer and was a member of the board of directors of Endocardial Solutions, Inc. (NASDAQ: ECSI), a cardiac-focused medical device company that was acquired by St. Jude Medical, which was itself acquired by Abbott Laboratories (NYSE: ABT). He also served in that position at Stuart Medical, Inc., and began his career working in a variety of sales and marketing leadership positions at Baxter International, Inc. (NYSE: BAX), and American Hospital Supply Corporation. In addition to his service on the board of Endocardial Solutions, Inc., Mr. Bullock has also served on the boards of directors of several private companies. Currently, in addition to CryoLife's Board of Directors, Mr. Bullock also serves as Chairman of the board of directors of Stimdia, Inc., a privately-held company that is conducting research for the development of medical devices for use in the critical care treatment of ventilator induced diaphragmatic dysfunction. Mr. Bullock also serves as a director for Surgical Information Science, Inc., a private health company, CardioNxt, Inc.,a private health company, and Intershunt Technologies, Inc., a private health company. Mr. Bullock received a B.S. in Public Administration from the University of Arizona. - JamesW.Bullock自2016年10月起担任CryoLife的董事。Bullock先生是Zyga Technology，Inc.的总裁兼首席执行官，该公司是一家私人控股的医疗设备公司，专注于治疗腰椎疾病的产品。他也担任Split Rock Partners LLC（风险投资公司，投资于医疗设备领域，专注于治疗设备）的常驻执行官。他自2011年以来担任这两个职位。此前，他曾担任Atritech，Inc.的总裁兼首席执行官6年。Atritech是一家私人持有的心血管制造公司，被Boston Scientific NYSE:BSX收购。在此之前，他在EndCardial Solutions，Inc.（纳斯达克市场代码:ECSI）担任了9年的总裁兼首席执行官，该公司是一家专注于心脏的医疗设备公司，被St.Jude Medical收购，后者被雅培公司（纽约证券交易所市场代码:ABT）收购。他还在Stuart Medical，Inc.担任该职位，并在Stackhouse，Inc.，Baxter梦百合，Inc.（NYSE:BAX）和American Hospital Supply Corporation担任多个销售领导职位。Bullock先生曾在七家私人公司和一家上市公司的董事会任职。目前，除了CryoLife的董事会，Bullock先生还担任Stimdia的董事会主席，该公司是Andarta Medical的一家私人控股的初创子公司，Inc.，该公司正在进行研究，以开发用于呼吸机引起的膈肌功能障碍的重症监护治疗的医疗器械。Bullock先生在亚利桑那大学（University of Arizona）获得公共管理学士学位。
- James W. Bullock has served as a director of CryoLife since October 2016. Mr. Bullock previously served as the President and Chief Executive Officer of Zyga Technology, Inc. "Zyga Technology", a privately-held medical device company focused on products that treat conditions of the lumbar spine, until January 2018 when RTI Surgical, Inc. (formerly NASDAQ: RTIX) acquired Zyga Technology. Prior to that, he served for six years as President and Chief Executive Officer of Atritech, Inc. Atritech was a privately-held cardiovascular manufacturing company that was acquired by Boston Scientific Corporation (NYSE: BSX). Prior to that, he served for nine years as President and Chief Executive Officer and was a member of the board of directors of Endocardial Solutions, Inc. (NASDAQ: ECSI), a cardiac-focused medical device company that was acquired by St. Jude Medical, which was itself acquired by Abbott Laboratories (NYSE: ABT). He also served in that position at Stuart Medical, Inc., and began his career working in a variety of sales and marketing leadership positions at Baxter International, Inc. (NYSE: BAX), and American Hospital Supply Corporation. In addition to his service on the board of Endocardial Solutions, Inc., Mr. Bullock has also served on the boards of directors of several private companies. Currently, in addition to CryoLife's Board of Directors, Mr. Bullock also serves as Chairman of the board of directors of Stimdia, Inc., a privately-held company that is conducting research for the development of medical devices for use in the critical care treatment of ventilator induced diaphragmatic dysfunction. Mr. Bullock also serves as a director for Surgical Information Science, Inc., a private health company, CardioNxt, Inc.,a private health company, and Intershunt Technologies, Inc., a private health company. Mr. Bullock received a B.S. in Public Administration from the University of Arizona.
- Marna P. Borgstrom
-
MarnaP.Borgstrom自2018年6月起担任CryoLife的董事。自2005年以来，Borgstrom女士一直担任Yale New Haven Health System的总裁，首席执行官和董事会成员，该公司是一家在康涅狄格州，西罗德岛州和纽约州威彻斯特县运营的综合医疗保健提供系统。此外，Borgstrom女士目前在几个国家认可的董事会任职，包括Vizient，Inc.（一家私人持有，成员驱动的医疗保健性能改进公司），the Coalition to Protect America’；s医疗保健，以及the医疗保健Institute。Borgstrom女士在斯坦福大学获得文学学士学位，并在耶鲁大学获得公共卫生硕士学位。
Marna P. Borgstrom has served as a director of CryoLife since June 2018. Since 2005 Ms. Borgstrom has been President, Chief Executive Officer, and a board member of the Yale New Haven Health System, an integrated health care delivery system that operates in Connecticut, western Rhode Island, and Westchester County, New York. Additionally, Ms. Borgstrom currently serves on several nationally recognized boards including Vizient, Inc., a privately held, member-driven healthcare performance improvement company, the Coalition to Protect America's Healthcare, and the Healthcare Institute. Ms. Borgstrom received her Bachelor of Arts from Stanford University and a Masters in Public Health from Yale University. - MarnaP.Borgstrom自2018年6月起担任CryoLife的董事。自2005年以来，Borgstrom女士一直担任Yale New Haven Health System的总裁，首席执行官和董事会成员，该公司是一家在康涅狄格州，西罗德岛州和纽约州威彻斯特县运营的综合医疗保健提供系统。此外，Borgstrom女士目前在几个国家认可的董事会任职，包括Vizient，Inc.（一家私人持有，成员驱动的医疗保健性能改进公司），the Coalition to Protect America’；s医疗保健，以及the医疗保健Institute。Borgstrom女士在斯坦福大学获得文学学士学位，并在耶鲁大学获得公共卫生硕士学位。
- Marna P. Borgstrom has served as a director of CryoLife since June 2018. Since 2005 Ms. Borgstrom has been President, Chief Executive Officer, and a board member of the Yale New Haven Health System, an integrated health care delivery system that operates in Connecticut, western Rhode Island, and Westchester County, New York. Additionally, Ms. Borgstrom currently serves on several nationally recognized boards including Vizient, Inc., a privately held, member-driven healthcare performance improvement company, the Coalition to Protect America's Healthcare, and the Healthcare Institute. Ms. Borgstrom received her Bachelor of Arts from Stanford University and a Masters in Public Health from Yale University.
- Elizabeth A. Hoff
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Anthony B. Semedo
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Jeffrey H. Burbank
-
Jeffrey H. Burbank，他在1998年创立了NxStage，并担任董事及首席执行官。他在公司发展，营销和为终末期肾脏疾病患者制造产品等方面拥有超过25年的的深入管理经验。自NxStage成立以来，他领导公司经历其所有的发展阶段，包括成功启动，商业活动的快速增长，首次公开募股，以及收购Medisystems Corporation。在建立NxStage之前，他联合创立了Vasca（该公司提供创新性的植入式接入设备），并担任总裁，首席执行官，以及公司董事会主席。他在Gambro（一家医疗技术公司）工作了9年，获得了重要的行业经验。他在Gambro最后的职位是营销和高级技术总监。
Jeffrey H. Burbank is Chief Executive Officer and a member of Board of Directors and has served in these positions since he founded the company in December 1998. Mr. Burbank has over 30 years of in-depth management experience with companies developing, marketing and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Prior to founding NxStage, Mr. Burbank co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., a medical technology company, with his last position as Director of Marketing and Advanced Technologies. During his career he has been an inventor on over 50 U.S. patents for medical devices. Mr. Burbank received his BS in Industrial Engineering from Lehigh University. - Jeffrey H. Burbank，他在1998年创立了NxStage，并担任董事及首席执行官。他在公司发展，营销和为终末期肾脏疾病患者制造产品等方面拥有超过25年的的深入管理经验。自NxStage成立以来，他领导公司经历其所有的发展阶段，包括成功启动，商业活动的快速增长，首次公开募股，以及收购Medisystems Corporation。在建立NxStage之前，他联合创立了Vasca（该公司提供创新性的植入式接入设备），并担任总裁，首席执行官，以及公司董事会主席。他在Gambro（一家医疗技术公司）工作了9年，获得了重要的行业经验。他在Gambro最后的职位是营销和高级技术总监。
- Jeffrey H. Burbank is Chief Executive Officer and a member of Board of Directors and has served in these positions since he founded the company in December 1998. Mr. Burbank has over 30 years of in-depth management experience with companies developing, marketing and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Prior to founding NxStage, Mr. Burbank co-founded Vasca, Inc., a company providing innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. He gained significant renal industry experience during his nine years in the Renal Division at Gambro, Inc., a medical technology company, with his last position as Director of Marketing and Advanced Technologies. During his career he has been an inventor on over 50 U.S. patents for medical devices. Mr. Burbank received his BS in Industrial Engineering from Lehigh University.
- Daniel J. Bevevino
-
Daniel J. Bevevino，自2003年12月起担任CryoLife的董事。从1996年到2008年3月，Bevevino先生在Respironics，Inc.担任副总裁兼首席财务官。1988年开始，他受雇于Respironics公司。2008年3月，Respironics被皇家飞利浦NYSE：PHG（“飞利浦”）收购。从2008年3月至2009年12月31日，Bevevino先生受雇于飞利浦，担任合并后整合-Respironics的负责人，并担任各种运营职务，以帮助促进合并后公司的整合。他目前是在生命科学行业提供临时首席财务官服务的独立顾问，他目前担任他所提供服务的其中一家私营公司的董事。他的职业生涯始于安永会计师事务所（Ernst & Young LLP）的注册会计师。Bevevino先生的执照目前处于无效状态。Bevevino先生获得杜肯大学工商管理学士学位和圣母大学硕士学位。
Daniel J. Bevevino has served as a director of CryoLife since December 2003. From 1996 until March 2008 Mr. Bevevino served as the Vice President and Chief Financial Officer of Respironics, Inc., a company that developed, manufactured and marketed medical devices used primarily for the treatment of patients suffering from sleep and respiratory disorders. He was employed by Respironics beginning in 1988. In March 2008 Respironics was acquired by Royal Philips NYSE: PHG ("Philips"), whose businesses included a variety of medical solutions including medical diagnostic imaging and patient monitoring systems, as well as businesses focused on energy efficient lighting and consumer products. From March 2008 to December 31 2009 Mr. Bevevino was employed by Philips as the Head of Post-Merger Integration - Respironics, as well as in various operating capacities, to help facilitate the integration of the combined companies. He is currently an independent consultant providing interim chief financial officer services in the life sciences industry, and he currently serves as a director of one of the private companies for which he provides services. He began his career as a Certified Public Accountant with Ernst & Young LLP. Mr. Bevevino's license is currently inactive. Mr. Bevevino received a B.S. in Business Administration from Duquesne University and an MBA from the University of Notre Dame. - Daniel J. Bevevino，自2003年12月起担任CryoLife的董事。从1996年到2008年3月，Bevevino先生在Respironics，Inc.担任副总裁兼首席财务官。1988年开始，他受雇于Respironics公司。2008年3月，Respironics被皇家飞利浦NYSE：PHG（“飞利浦”）收购。从2008年3月至2009年12月31日，Bevevino先生受雇于飞利浦，担任合并后整合-Respironics的负责人，并担任各种运营职务，以帮助促进合并后公司的整合。他目前是在生命科学行业提供临时首席财务官服务的独立顾问，他目前担任他所提供服务的其中一家私营公司的董事。他的职业生涯始于安永会计师事务所（Ernst & Young LLP）的注册会计师。Bevevino先生的执照目前处于无效状态。Bevevino先生获得杜肯大学工商管理学士学位和圣母大学硕士学位。
- Daniel J. Bevevino has served as a director of CryoLife since December 2003. From 1996 until March 2008 Mr. Bevevino served as the Vice President and Chief Financial Officer of Respironics, Inc., a company that developed, manufactured and marketed medical devices used primarily for the treatment of patients suffering from sleep and respiratory disorders. He was employed by Respironics beginning in 1988. In March 2008 Respironics was acquired by Royal Philips NYSE: PHG ("Philips"), whose businesses included a variety of medical solutions including medical diagnostic imaging and patient monitoring systems, as well as businesses focused on energy efficient lighting and consumer products. From March 2008 to December 31 2009 Mr. Bevevino was employed by Philips as the Head of Post-Merger Integration - Respironics, as well as in various operating capacities, to help facilitate the integration of the combined companies. He is currently an independent consultant providing interim chief financial officer services in the life sciences industry, and he currently serves as a director of one of the private companies for which he provides services. He began his career as a Certified Public Accountant with Ernst & Young LLP. Mr. Bevevino's license is currently inactive. Mr. Bevevino received a B.S. in Business Administration from Duquesne University and an MBA from the University of Notre Dame.
- James P. Mackin
-
JamesP.Mackin于2014年9月担任总裁兼首席执行官，并于2014年10月被任命为董事会成员。Mackin先生在医疗器械行业拥有超过20年的经验。在加入CryoLife公司之前，麦金先生曾担任美敦力公司最大的业务部门心脏节律疾病管理公司的总裁在美敦力之前，他曾担任西欧和Vice President血管Vice President和血管内业务部门总经理。在2002年加入美敦力之前，Mackin先生在Genzyme，Inc.工作了六年，担任心血管外科业务部的高级副总裁和总经理，并担任外科产品部的销售总监。在加入Genzyme之前，Mackin先生在Deknatel/Snowden-Pencer，Inc.担任了四年的各种职务，并在美国陆军担任了三年的中尉。Mackin先生在西北大学凯洛格管理研究生院（Northwestern University&8217；S Kellogg Graduate School of Management）获得工商管理硕士学位，并是西点军校（the U.S.Military Academy at West Point）的毕业生。
James P. Mackin assumed the position of President and Chief Executive Officer in September 2014 and was appointed to the Board of Directors in October 2014. Mr. Mackin has more than 20 years of experience in the medical device industry. Prior to joining CryoLife, Mr. Mackin served as President of Cardiac Rhythm Disease Management, the largest operating division of Medtronic, Inc. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002 Mr. Mackin worked for six years at Genzyme, Inc. serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr. Mackin spent four years at Deknatel/Snowden-Pencer, Inc. in various roles and three years as a First Lieutenant in the U.S. Army. Mr. Mackin received an MBA from Northwestern University’s Kellogg Graduate School of Management and is a graduate of the U.S. Military Academy at West Point. - JamesP.Mackin于2014年9月担任总裁兼首席执行官，并于2014年10月被任命为董事会成员。Mackin先生在医疗器械行业拥有超过20年的经验。在加入CryoLife公司之前，麦金先生曾担任美敦力公司最大的业务部门心脏节律疾病管理公司的总裁在美敦力之前，他曾担任西欧和Vice President血管Vice President和血管内业务部门总经理。在2002年加入美敦力之前，Mackin先生在Genzyme，Inc.工作了六年，担任心血管外科业务部的高级副总裁和总经理，并担任外科产品部的销售总监。在加入Genzyme之前，Mackin先生在Deknatel/Snowden-Pencer，Inc.担任了四年的各种职务，并在美国陆军担任了三年的中尉。Mackin先生在西北大学凯洛格管理研究生院（Northwestern University&8217；S Kellogg Graduate School of Management）获得工商管理硕士学位，并是西点军校（the U.S.Military Academy at West Point）的毕业生。
- James P. Mackin assumed the position of President and Chief Executive Officer in September 2014 and was appointed to the Board of Directors in October 2014. Mr. Mackin has more than 20 years of experience in the medical device industry. Prior to joining CryoLife, Mr. Mackin served as President of Cardiac Rhythm Disease Management, the largest operating division of Medtronic, Inc. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002 Mr. Mackin worked for six years at Genzyme, Inc. serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr. Mackin spent four years at Deknatel/Snowden-Pencer, Inc. in various roles and three years as a First Lieutenant in the U.S. Army. Mr. Mackin received an MBA from Northwestern University’s Kellogg Graduate School of Management and is a graduate of the U.S. Military Academy at West Point.
- Thomas F. Ackerman
-
Thomas F. Ackerman，自2003年12月起担任CryoLife的董事。在2017年2月之前，Ackerman先生一直担任Charles River Laboratories International, Inc. NYSE：CRL（“Charles River Laboratories”）的顾问。Charles River Laboratories是加速早期药物发现和开发过程的解决方案的全球领先供应商，专注于体内生物学，包括实现体内药物发现和开发所需的研究模型和服务。直到2016年初，Ackerman先生一直担任Charles River Laboratories的高级财务顾问。2005年至2015年，担任Charles River Laboratories执行副总裁兼首席财务官。1999年至2005年，担任Charles River Laboratories高级副总裁兼首席财务官。Ackerman先生于1996年至1999年期间担任Charles River Laboratories的副总裁兼首席财务官，自1988年起受雇于该公司。Ackerman先生是马萨诸塞大学阿默斯特基金会的董事，并在欧林工程学院的审计委员会任职。Ackerman先生获得了马萨诸塞大学会计学学士学位，并于1979年成为一名注册会计师。阿克曼先生的执照目前处于无效状态。
Thomas F. Ackerman has served as a director of CryoLife since December 2003. Until February 2017 Mr. Ackerman served as a consultant to Charles River Laboratories International, Inc. NYSE: CRL ("Charles River Laboratories"). Charles River Laboratories is a leading global provider of solutions that accelerate the early-stage drug discovery and development process, with a focus on in vivo biology, including research models and services required to enable in vivo drug discovery and development. Until early 2016 Mr. Ackerman served as a Senior Financial Advisor of Charles River Laboratories, a position he held since August 2015. From 2005 to 2015 he served as Executive Vice President and Chief Financial Officer of Charles River Laboratories. From 1999 to 2005 he served as Senior Vice President and Chief Financial Officer of Charles River Laboratories. Mr. Ackerman served as Vice President and Chief Financial Officer of Charles River Laboratories from 1996 to 1999 where he was employed since 1988. Mr. Ackerman is a director of the University of Massachusetts Amherst Foundation and serves on the audit committee of Olin College of Engineering. Mr. Ackerman received a B.S. in Accounting from the University of Massachusetts and became a Certified Public Accountant in 1979. Mr. Ackerman's license is currently inactive. - Thomas F. Ackerman，自2003年12月起担任CryoLife的董事。在2017年2月之前，Ackerman先生一直担任Charles River Laboratories International, Inc. NYSE：CRL（“Charles River Laboratories”）的顾问。Charles River Laboratories是加速早期药物发现和开发过程的解决方案的全球领先供应商，专注于体内生物学，包括实现体内药物发现和开发所需的研究模型和服务。直到2016年初，Ackerman先生一直担任Charles River Laboratories的高级财务顾问。2005年至2015年，担任Charles River Laboratories执行副总裁兼首席财务官。1999年至2005年，担任Charles River Laboratories高级副总裁兼首席财务官。Ackerman先生于1996年至1999年期间担任Charles River Laboratories的副总裁兼首席财务官，自1988年起受雇于该公司。Ackerman先生是马萨诸塞大学阿默斯特基金会的董事，并在欧林工程学院的审计委员会任职。Ackerman先生获得了马萨诸塞大学会计学学士学位，并于1979年成为一名注册会计师。阿克曼先生的执照目前处于无效状态。
- Thomas F. Ackerman has served as a director of CryoLife since December 2003. Until February 2017 Mr. Ackerman served as a consultant to Charles River Laboratories International, Inc. NYSE: CRL ("Charles River Laboratories"). Charles River Laboratories is a leading global provider of solutions that accelerate the early-stage drug discovery and development process, with a focus on in vivo biology, including research models and services required to enable in vivo drug discovery and development. Until early 2016 Mr. Ackerman served as a Senior Financial Advisor of Charles River Laboratories, a position he held since August 2015. From 2005 to 2015 he served as Executive Vice President and Chief Financial Officer of Charles River Laboratories. From 1999 to 2005 he served as Senior Vice President and Chief Financial Officer of Charles River Laboratories. Mr. Ackerman served as Vice President and Chief Financial Officer of Charles River Laboratories from 1996 to 1999 where he was employed since 1988. Mr. Ackerman is a director of the University of Massachusetts Amherst Foundation and serves on the audit committee of Olin College of Engineering. Mr. Ackerman received a B.S. in Accounting from the University of Massachusetts and became a Certified Public Accountant in 1979. Mr. Ackerman's license is currently inactive.
- Jon W. Salveson
-
Jon W. Salveson， 2012年5月以来，他一直担任CryoLife的董事。他是Piper Sandler Companies（纽约证券交易所代码：PIPR）（前Piper Jaffray公司，美国投资银行和资产管理公司）的投资银行副主席和医疗保健投资银行集团主席。他自2010年7月起担任副董事长，负责投资银行业务。他于2004年被任命为Piper Jaffray的投资银行业务全球主管和执行委员会成员。他于1993年加入Piper Jaffray，担任合伙人，1999年当选为董事总经理，2001年被任命为Piper Jaffray国际医疗保健投资银行集团的集团主管。Salveson先生还担任CHF Solutions， Inc.（纳斯达克股票代码：CHFS）的董事会成员，这是一家早期医疗设备公司。Salveson先生最近担任Asklepios biopharmacics， Inc.（一家专门从事基因治疗技术的私人公司，于2020年被Bayer AG （ETR： BAYN）收购）的董事会成员。Salveson先生于1987年获得St. Olaf College的本科学位，以及Northwestern大学凯洛格管理研究生院的金融硕士学位。
Jon W. Salveson has served as a director of CryoLife since May 2012. Mr. Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Sandler Companies NYSE: PIPR ("Piper Sandler"), formerly Piper Jaffray Companies, a U.S. investment bank and asset management firm. Mr. Salveson has served in his present position as Vice Chairman, Investment Banking since July 2010. Mr. Salveson was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004. He joined Piper Jaffray in 1993 as an associate, was elected Managing Director in 1999 and was named the Group Head of Piper Jaffray's international healthcare investment banking group in 2001. Mr. Salveson also serves on the Board of Directors of CHF Solutions, Inc. (NASDAQ: CHFS), an early-stage medical device company. Mr. Salveson recently served on the board of Asklepios Biopharmaceuticals, Inc., a private company specializing in gene therapy technologies, which was acquired by Bayer AG (ETR: BAYN) in 2020. Mr. Salveson received his undergraduate degree from St. Olaf College in 1987 and an M.M.M. in finance from the Kellogg Graduate School of Management at Northwestern University. - Jon W. Salveson， 2012年5月以来，他一直担任CryoLife的董事。他是Piper Sandler Companies（纽约证券交易所代码：PIPR）（前Piper Jaffray公司，美国投资银行和资产管理公司）的投资银行副主席和医疗保健投资银行集团主席。他自2010年7月起担任副董事长，负责投资银行业务。他于2004年被任命为Piper Jaffray的投资银行业务全球主管和执行委员会成员。他于1993年加入Piper Jaffray，担任合伙人，1999年当选为董事总经理，2001年被任命为Piper Jaffray国际医疗保健投资银行集团的集团主管。Salveson先生还担任CHF Solutions， Inc.（纳斯达克股票代码：CHFS）的董事会成员，这是一家早期医疗设备公司。Salveson先生最近担任Asklepios biopharmacics， Inc.（一家专门从事基因治疗技术的私人公司，于2020年被Bayer AG （ETR： BAYN）收购）的董事会成员。Salveson先生于1987年获得St. Olaf College的本科学位，以及Northwestern大学凯洛格管理研究生院的金融硕士学位。
- Jon W. Salveson has served as a director of CryoLife since May 2012. Mr. Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Sandler Companies NYSE: PIPR ("Piper Sandler"), formerly Piper Jaffray Companies, a U.S. investment bank and asset management firm. Mr. Salveson has served in his present position as Vice Chairman, Investment Banking since July 2010. Mr. Salveson was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004. He joined Piper Jaffray in 1993 as an associate, was elected Managing Director in 1999 and was named the Group Head of Piper Jaffray's international healthcare investment banking group in 2001. Mr. Salveson also serves on the Board of Directors of CHF Solutions, Inc. (NASDAQ: CHFS), an early-stage medical device company. Mr. Salveson recently served on the board of Asklepios Biopharmaceuticals, Inc., a private company specializing in gene therapy technologies, which was acquired by Bayer AG (ETR: BAYN) in 2020. Mr. Salveson received his undergraduate degree from St. Olaf College in 1987 and an M.M.M. in finance from the Kellogg Graduate School of Management at Northwestern University.
高管简历
中英对照 | 中文 | 英文- John E. Davis
John E. Davis，他于2015年9月被任命为高级副总裁，负责全球销售和营销。他拥有超过20年的销售和市场营销和行政领导经验。加入CryoLife公司之前，他曾担任CorMatrix公司（私营医疗设备公司，创建创新的生物材料设备，用于修复受损的心脏组织）的执行副总裁，负责销售和营销（2012年3月至2015年9月）。任职CorMatrix公司之前，他曾担任St. Jude Medical公司的销售副总裁4年，负责心脏节律管理设备业务。任职St. Jude Medical公司之前，他曾任职Medtronic公司的心脏节律疾病管理部门14年，担任高级销售领导职务。职业生涯早期，他曾任职Roche Diagnostics、Ciba-Geigy Corporation。他持有Western Carolina University的学士学位。
John E. Davis assumed the position of Senior Vice President, Global Sales and Marketing in September 2015 and was appointed to the position of Chief Commercial Officer in February 2024. He has over 25 years of experience in Sales and Marketing and Executive Leadership. Prior to joining Artivion, he served as Executive Vice President, Global Sales and Marketing at CorMatrix, a privately held medical device company creating innovative biomaterial devices to repair damaged heart tissue from March 2012 to September 2015. Prior to CorMatrix, he served f years as a Vice President of Sales in the Cardiac Rhythm Management biness at St. Jude Medical, now part of Abbott Laboratories. Before St. Jude Medical, he served 14 years with Medtronic in the Cardiac Rhythm Disease Management division including 7 years as Vice President Southeast. In his early career he held sales and leadership roles with Roche Diagnostics and Ciba Geigy Corporation. Mr. Davis received a Bachelor's degree from stern Carolina University.- John E. Davis，他于2015年9月被任命为高级副总裁，负责全球销售和营销。他拥有超过20年的销售和市场营销和行政领导经验。加入CryoLife公司之前，他曾担任CorMatrix公司（私营医疗设备公司，创建创新的生物材料设备，用于修复受损的心脏组织）的执行副总裁，负责销售和营销（2012年3月至2015年9月）。任职CorMatrix公司之前，他曾担任St. Jude Medical公司的销售副总裁4年，负责心脏节律管理设备业务。任职St. Jude Medical公司之前，他曾任职Medtronic公司的心脏节律疾病管理部门14年，担任高级销售领导职务。职业生涯早期，他曾任职Roche Diagnostics、Ciba-Geigy Corporation。他持有Western Carolina University的学士学位。
- John E. Davis assumed the position of Senior Vice President, Global Sales and Marketing in September 2015 and was appointed to the position of Chief Commercial Officer in February 2024. He has over 25 years of experience in Sales and Marketing and Executive Leadership. Prior to joining Artivion, he served as Executive Vice President, Global Sales and Marketing at CorMatrix, a privately held medical device company creating innovative biomaterial devices to repair damaged heart tissue from March 2012 to September 2015. Prior to CorMatrix, he served f years as a Vice President of Sales in the Cardiac Rhythm Management biness at St. Jude Medical, now part of Abbott Laboratories. Before St. Jude Medical, he served 14 years with Medtronic in the Cardiac Rhythm Disease Management division including 7 years as Vice President Southeast. In his early career he held sales and leadership roles with Roche Diagnostics and Ciba Geigy Corporation. Mr. Davis received a Bachelor's degree from stern Carolina University.
- Amy D. Horton
Amy D. Horton，她曾一直担任CryoLife公司的首席会计官（2006年以来）。她一直任职公司（1998年1月以来），担任总会计师（从2000年4月到2006年8月），以及助理总会计师。从1993年到1998年，她曾担任Ernst & Young LLP的注册会计师。她持有Brigham Young University（位于犹她州普洛佛）的会计学士学位和硕士学位。
Amy D. Horton was appointed to the position of Vice President and Chief Accounting Officer in January 2016 and had previoly served as Chief Accounting Officer of Artivion since 2006. Ms. Horton has been with the Company since January 1998, serving as Controller from April 2000 to August 2006, and as Assistant Controller prior to that. From 1993 to 1998, Ms. Horton was employed as a Certified Public Accountant with Ernst & Young, LLP. She received her Bachelor's and Master's degrees in Accounting from Brigham Young University in Provo, Utah.- Amy D. Horton，她曾一直担任CryoLife公司的首席会计官（2006年以来）。她一直任职公司（1998年1月以来），担任总会计师（从2000年4月到2006年8月），以及助理总会计师。从1993年到1998年，她曾担任Ernst & Young LLP的注册会计师。她持有Brigham Young University（位于犹她州普洛佛）的会计学士学位和硕士学位。
- Amy D. Horton was appointed to the position of Vice President and Chief Accounting Officer in January 2016 and had previoly served as Chief Accounting Officer of Artivion since 2006. Ms. Horton has been with the Company since January 1998, serving as Controller from April 2000 to August 2006, and as Assistant Controller prior to that. From 1993 to 1998, Ms. Horton was employed as a Certified Public Accountant with Ernst & Young, LLP. She received her Bachelor's and Master's degrees in Accounting from Brigham Young University in Provo, Utah.
- Lance A. Berry
Lance A. Berry于2025年8月被任命为执行副总裁、首席运营官、首席财务官和财务主管。在此之前，Berry先生自2023年12月4日起担任Artivion财务首席财务官兼执行副总裁。在加入Artivion之前，Berry先生曾在2019年1月至2020年11月期间担任执行副总裁、Wright Medical Group N.V。的首席财务和运营官，当时Wright被史赛克 NV收购。Berry先生在成为执行副总裁、首席财务和运营官之前，曾在Wright医疗担任以下职务：高级副总裁、首席财务官（2009-2018年）以及副总裁、公司控制人（2002-2009年）。Berry先生于1995年至2002年期间受雇于Arthur Anderson担任注册会计师。Berry先生目前在Treace Medical概念（NASDAQ：TCMI）董事会任职。Berry先生在密西西比大学获得了会计学硕士和学士学位。
Lance A. Berry was appointed to the position of Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer in August 2025. Before that, Mr. Berry served as the Chief Financial Officer and Executive Vice President, Finance of Artivion beginning December 4, 2023. Prior to joining Artivion, Mr. Berry served as the Executive Vice President, Chief Financial and Operations Officer of Wright Medical Group N.V., from January 2019 until November 2020, when Wright was acquired by Stryker NV. Before becoming Executive Vice President, Chief Financial and Operations Officer, Mr. Berry served in the following roles at Wright Medical: Senior Vice President, Chief Financial Officer (2009 2018) and Vice President, Corporate Controller (2002 2009). Mr. Berry was employed as a Certified Public Accountant with Arthur Anderson from 1995 to 2002. Mr. Berry currently serves on the Board of Treace Medical Concepts (NASDAQ: TCMI). Mr. Berry received both his Masters and Bachelor's in Accounting from the University of Mississippi.- Lance A. Berry于2025年8月被任命为执行副总裁、首席运营官、首席财务官和财务主管。在此之前，Berry先生自2023年12月4日起担任Artivion财务首席财务官兼执行副总裁。在加入Artivion之前，Berry先生曾在2019年1月至2020年11月期间担任执行副总裁、Wright Medical Group N.V。的首席财务和运营官，当时Wright被史赛克 NV收购。Berry先生在成为执行副总裁、首席财务和运营官之前，曾在Wright医疗担任以下职务：高级副总裁、首席财务官（2009-2018年）以及副总裁、公司控制人（2002-2009年）。Berry先生于1995年至2002年期间受雇于Arthur Anderson担任注册会计师。Berry先生目前在Treace Medical概念（NASDAQ：TCMI）董事会任职。Berry先生在密西西比大学获得了会计学硕士和学士学位。
- Lance A. Berry was appointed to the position of Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer in August 2025. Before that, Mr. Berry served as the Chief Financial Officer and Executive Vice President, Finance of Artivion beginning December 4, 2023. Prior to joining Artivion, Mr. Berry served as the Executive Vice President, Chief Financial and Operations Officer of Wright Medical Group N.V., from January 2019 until November 2020, when Wright was acquired by Stryker NV. Before becoming Executive Vice President, Chief Financial and Operations Officer, Mr. Berry served in the following roles at Wright Medical: Senior Vice President, Chief Financial Officer (2009 2018) and Vice President, Corporate Controller (2002 2009). Mr. Berry was employed as a Certified Public Accountant with Arthur Anderson from 1995 to 2002. Mr. Berry currently serves on the Board of Treace Medical Concepts (NASDAQ: TCMI). Mr. Berry received both his Masters and Bachelor's in Accounting from the University of Mississippi.
- Matthew A. Getz
MatthewA.Getz于2019年8月被任命为人力资源Vice President。加入CryoLife公司之前，他曾担任Encompass Digital Media公司的首席人力资源官，也曾担任SunTrust Bank、Xiocom Wireless公司、Earthlink公司和BlessingWhite公司的高级人力资源职务。Getz先生持有Georgia State University的工商管理硕士学位，专注于组织管理和国际业务，以及Mercer University的会计学工商管理学士学位。
Matthew A. Getz was appointed to the position of Vice President, Human Resces in August 2019. Prior to joining Artivion, he served as the Chief Human Resces Officer of Encompass Digital Media and has held senior human resces roles at SunTrt Bank, Xiocom Wireless, Earthlink and BlessingWhite. Mr. Getz holds an MBA with a concentration in organizational management and international biness from Georgia State University and a BBA in accounting from Mercer University.- MatthewA.Getz于2019年8月被任命为人力资源Vice President。加入CryoLife公司之前，他曾担任Encompass Digital Media公司的首席人力资源官，也曾担任SunTrust Bank、Xiocom Wireless公司、Earthlink公司和BlessingWhite公司的高级人力资源职务。Getz先生持有Georgia State University的工商管理硕士学位，专注于组织管理和国际业务，以及Mercer University的会计学工商管理学士学位。
- Matthew A. Getz was appointed to the position of Vice President, Human Resces in August 2019. Prior to joining Artivion, he served as the Chief Human Resces Officer of Encompass Digital Media and has held senior human resces roles at SunTrt Bank, Xiocom Wireless, Earthlink and BlessingWhite. Mr. Getz holds an MBA with a concentration in organizational management and international biness from Georgia State University and a BBA in accounting from Mercer University.
- Rochelle L. Maney
Rochelle L. Maney于2021年3月担任全球质量副总裁，并于2025年8月被任命为质量体系和组织质量副总裁。她在医疗设备和组织工业领域拥有超过25年的经验，自2000年以来一直在公司担任多个领导职务，最近担任乔治亚州、德克萨斯州和德国制造工厂质量副总裁。她是Quality在战略、勤勉和收购方面的首席执行官，负责公司在佐治亚州、德克萨斯州和德国赫钦根的三个制造工厂的所有质量体系职能。Maney女士是美国质量协会的成员，在美国纸巾银行协会的质量委员会和组织政策小组任职。她在贝瑞学院获得生物学理学学士学位。
Rochelle L. Maney assumed the position of Vice President, Global Quality in March 2021 and was appointed to the position of Vice President, Quality Systems and Tissue Quality in Augt 2025. She has over 25 years of experience in the medical device and tissue indtries and has been with the Company since 2000 serving in multiple leadership roles, most recently as Vice President, Quality for the Georgia, Texas, and Germany manufacturing facilities. She is the lead executive for Quality in strategy, diligence, and acquisitions and is responsible for all quality system functions at the Company's three manufacturing facilities in Georgia, Texas, and Hechingen, Germany. Ms. Maney is a member of the American Society of Quality and serves on the Quality Council and Tissue Policy Group for the American Association of Tissue Banks. She received her Bachelor of Science in Biology degree from Berry College.- Rochelle L. Maney于2021年3月担任全球质量副总裁，并于2025年8月被任命为质量体系和组织质量副总裁。她在医疗设备和组织工业领域拥有超过25年的经验，自2000年以来一直在公司担任多个领导职务，最近担任乔治亚州、德克萨斯州和德国制造工厂质量副总裁。她是Quality在战略、勤勉和收购方面的首席执行官，负责公司在佐治亚州、德克萨斯州和德国赫钦根的三个制造工厂的所有质量体系职能。Maney女士是美国质量协会的成员，在美国纸巾银行协会的质量委员会和组织政策小组任职。她在贝瑞学院获得生物学理学学士学位。
- Rochelle L. Maney assumed the position of Vice President, Global Quality in March 2021 and was appointed to the position of Vice President, Quality Systems and Tissue Quality in Augt 2025. She has over 25 years of experience in the medical device and tissue indtries and has been with the Company since 2000 serving in multiple leadership roles, most recently as Vice President, Quality for the Georgia, Texas, and Germany manufacturing facilities. She is the lead executive for Quality in strategy, diligence, and acquisitions and is responsible for all quality system functions at the Company's three manufacturing facilities in Georgia, Texas, and Hechingen, Germany. Ms. Maney is a member of the American Society of Quality and serves on the Quality Council and Tissue Policy Group for the American Association of Tissue Banks. She received her Bachelor of Science in Biology degree from Berry College.
- Florian Tyrs
Florian Tyrs于2023年6月被任命为全球运营副总裁。Tyrs先生在医疗器械工业领域拥有超过15年的经验。Tyrs先生自2006年3月起任职于Artivion。2020年7月至今任河清根场址总经理。Tyrs先生还曾于2023年1月至2023年6月担任赫钦根运营副总裁；于2018年1月至2022年12月担任运营总监；于2011年5月至2017年12月担任生产总监；于2011年11月至2017年12月担任设施管理和制造工程总监，于2010年4月至2011年4月担任生产副总监，于2009年4月至2011年4月担任精益生产经理。从2006年3月到2009年3月，Tyrs先生受雇于Artivion血管内支架移植产品组合的研发工程师。Tyrs先生拥有德国阿尔布施塔特Sigmaringen国立应用科学大学制药工程文凭。
Florian Tyrs was appointed to the position of Vice President, Global Operations in June 2023. Mr. Tyrs has more than 15 years of experience in the medical device industry. Mr. Tyrs has been with Artivion since March 2006. He has served as General Manager of the Hechingen Site since July 2020. Mr. Tyrs has also served as a Vice President Hechingen Operations from January 2023 to June 2023; as Director Operations from January 2018 to December 2022; as Director Production from May 2011 to December 2017; as Director Facility Management and Manufacturing Engineering from November 2011 to December 2017, as Deputy Director Production from April 2010 to April 2011, as Lean Production Manager from April 2009 to April 2011. From March 2006 to March 2009, Mr. Tyrs was employed as an R&D Engineer for the Endovascular Stentgraft Portfolio of Artivion. Mr. Tyrs holds a Diploma in Pharmaceutical Engineering of the State University of Applied Science in Albstadt Sigmaringen, Germany.- Florian Tyrs于2023年6月被任命为全球运营副总裁。Tyrs先生在医疗器械工业领域拥有超过15年的经验。Tyrs先生自2006年3月起任职于Artivion。2020年7月至今任河清根场址总经理。Tyrs先生还曾于2023年1月至2023年6月担任赫钦根运营副总裁；于2018年1月至2022年12月担任运营总监；于2011年5月至2017年12月担任生产总监；于2011年11月至2017年12月担任设施管理和制造工程总监，于2010年4月至2011年4月担任生产副总监，于2009年4月至2011年4月担任精益生产经理。从2006年3月到2009年3月，Tyrs先生受雇于Artivion血管内支架移植产品组合的研发工程师。Tyrs先生拥有德国阿尔布施塔特Sigmaringen国立应用科学大学制药工程文凭。
- Florian Tyrs was appointed to the position of Vice President, Global Operations in June 2023. Mr. Tyrs has more than 15 years of experience in the medical device industry. Mr. Tyrs has been with Artivion since March 2006. He has served as General Manager of the Hechingen Site since July 2020. Mr. Tyrs has also served as a Vice President Hechingen Operations from January 2023 to June 2023; as Director Operations from January 2018 to December 2022; as Director Production from May 2011 to December 2017; as Director Facility Management and Manufacturing Engineering from November 2011 to December 2017, as Deputy Director Production from April 2010 to April 2011, as Lean Production Manager from April 2009 to April 2011. From March 2006 to March 2009, Mr. Tyrs was employed as an R&D Engineer for the Endovascular Stentgraft Portfolio of Artivion. Mr. Tyrs holds a Diploma in Pharmaceutical Engineering of the State University of Applied Science in Albstadt Sigmaringen, Germany.
- Andrew M. Green
Andrew M. Green于2021年3月担任监管事务副总裁，并于2025年8月被任命为监管和质量高级副总裁。Green先生在医疗器械和生物制剂工业方面拥有30多年的监管、临床、质量和BINES经验。更具体地说，他在FDA做了3年心血管器械分支的科学复发者，在Novoste Corporation做了将近10年的监管、临床和质量副总裁，还有5年为医疗器械公司提供监管、临床和质量咨询服务。格林先生还拥有广泛的BINGS经验，曾担任CorMatrix心血管总裁兼首席运营官数年，最终担任其首席执行官。在Aziyo Biologics收购CorMatrix资产后，Green先生继续在Aziyo担任多个职务，包括担任监管和医疗事务执行副总裁。他的职业生涯始于在陆军和陆军预备役中担任战斗军医。格林先生拥有生物科学学士学位和生物工程硕士学位，均来自克莱姆森大学。
Andrew M. Green assumed the position of Vice President, Regulatory Affairs in March 2021 and was appointed to the position of Senior Vice President, Regulatory and Quality in August 2025. Mr. Green has more than 30 years of regulatory, clinical, quality, and biness experience in the medical device and biologics industry. More specifically, he spent 3 years at the FDA as a scientific revier in the cardiovascular devices branch, almost 10 years at Novoste Corporation as the Vice President of Regulatory, Clinical, and Quality, and five years providing regulatory, clinical, and quality consulting services to medical device companies. Mr. Green also has broad biness experience, having served as the President and COO of CorMatrix Cardiovascular for several years before ultimately serving as its CEO. After the acquisition of the CorMatrix assets by Aziyo Biologics, Mr. Green continued with Aziyo in several roles, including as the Executive Vice President of Regulatory and Medical Affairs. He started his career serving as a combat medic in the Army and Army Reserves. Mr. Green has a Bachelor in Biological Sciences and a Master's in Bioengineering, both from Clemson University.- Andrew M. Green于2021年3月担任监管事务副总裁，并于2025年8月被任命为监管和质量高级副总裁。Green先生在医疗器械和生物制剂工业方面拥有30多年的监管、临床、质量和BINES经验。更具体地说，他在FDA做了3年心血管器械分支的科学复发者，在Novoste Corporation做了将近10年的监管、临床和质量副总裁，还有5年为医疗器械公司提供监管、临床和质量咨询服务。格林先生还拥有广泛的BINGS经验，曾担任CorMatrix心血管总裁兼首席运营官数年，最终担任其首席执行官。在Aziyo Biologics收购CorMatrix资产后，Green先生继续在Aziyo担任多个职务，包括担任监管和医疗事务执行副总裁。他的职业生涯始于在陆军和陆军预备役中担任战斗军医。格林先生拥有生物科学学士学位和生物工程硕士学位，均来自克莱姆森大学。
- Andrew M. Green assumed the position of Vice President, Regulatory Affairs in March 2021 and was appointed to the position of Senior Vice President, Regulatory and Quality in August 2025. Mr. Green has more than 30 years of regulatory, clinical, quality, and biness experience in the medical device and biologics industry. More specifically, he spent 3 years at the FDA as a scientific revier in the cardiovascular devices branch, almost 10 years at Novoste Corporation as the Vice President of Regulatory, Clinical, and Quality, and five years providing regulatory, clinical, and quality consulting services to medical device companies. Mr. Green also has broad biness experience, having served as the President and COO of CorMatrix Cardiovascular for several years before ultimately serving as its CEO. After the acquisition of the CorMatrix assets by Aziyo Biologics, Mr. Green continued with Aziyo in several roles, including as the Executive Vice President of Regulatory and Medical Affairs. He started his career serving as a combat medic in the Army and Army Reserves. Mr. Green has a Bachelor in Biological Sciences and a Master's in Bioengineering, both from Clemson University.
- Robert C. Thon
Robert C. Thon于2023年6月被任命为研发副总裁。Dr. Thomson带来了在医疗器械工业领域超过25年的多样化研发、技术、营销和biness经验。在W.L. Gore的职业生涯中，他成功开发并在全球范围内商业化了几种心血管设备，包括组合产品。在过渡到主动脉疗法的开发之前，Thomson博士曾担任领导外周血管设备研发团队和binesses的高级主管数年。在此期间，他担任高级管理职位，领导团队专注于开发血管内产品组合。在加入Artivion之前，他最近领导心脏和血管研发和服务开发团队，同时还在执行医疗器械审查委员会任职。汤姆森博士拥有2项专利，并撰写了15篇同行审查的科学出版物。他在莱斯大学获得生物医学工程学博士学位，目前担任生物工程顾问委员会成员，并拥有苏格兰爱丁堡大学化学工程学理学学士学位。
Robert C. Thon was appointed to the position of Vice President, Research and Development in June of 2023. During his career at W.L. Gore, he successfully developed and globally commercialized several cardiovascular devices, including combination products. Dr. Thomson served as a senior director leading Peripheral vascular device R&D teams and binesses for several years before transitioning into the development of Aortic therapies. During this period, he held a senior management position leading teams foced on the development of an endovascular product portfolio. Prior to joining Artivion, he most recently led cardiac and vascular R&D and service development teams while also serving on an executive medical device review board. Dr. Thomson has held 2 patents and has authored 15 peer revied scientific publications. He received his Ph.D. in Biomedical Engineering from Rice University, where he currently serves as a Bioengineering Advisory Board Member and holds a Bachelor of Science in Chemical Engineering from the University of Edinburgh in Scotland.- Robert C. Thon于2023年6月被任命为研发副总裁。Dr. Thomson带来了在医疗器械工业领域超过25年的多样化研发、技术、营销和biness经验。在W.L. Gore的职业生涯中，他成功开发并在全球范围内商业化了几种心血管设备，包括组合产品。在过渡到主动脉疗法的开发之前，Thomson博士曾担任领导外周血管设备研发团队和binesses的高级主管数年。在此期间，他担任高级管理职位，领导团队专注于开发血管内产品组合。在加入Artivion之前，他最近领导心脏和血管研发和服务开发团队，同时还在执行医疗器械审查委员会任职。汤姆森博士拥有2项专利，并撰写了15篇同行审查的科学出版物。他在莱斯大学获得生物医学工程学博士学位，目前担任生物工程顾问委员会成员，并拥有苏格兰爱丁堡大学化学工程学理学学士学位。
- Robert C. Thon was appointed to the position of Vice President, Research and Development in June of 2023. During his career at W.L. Gore, he successfully developed and globally commercialized several cardiovascular devices, including combination products. Dr. Thomson served as a senior director leading Peripheral vascular device R&D teams and binesses for several years before transitioning into the development of Aortic therapies. During this period, he held a senior management position leading teams foced on the development of an endovascular product portfolio. Prior to joining Artivion, he most recently led cardiac and vascular R&D and service development teams while also serving on an executive medical device review board. Dr. Thomson has held 2 patents and has authored 15 peer revied scientific publications. He received his Ph.D. in Biomedical Engineering from Rice University, where he currently serves as a Bioengineering Advisory Board Member and holds a Bachelor of Science in Chemical Engineering from the University of Edinburgh in Scotland.
- James P. Mackin
JamesP.Mackin于2014年9月担任总裁兼首席执行官，并于2014年10月被任命为董事会成员。Mackin先生在医疗器械行业拥有超过20年的经验。在加入CryoLife公司之前，麦金先生曾担任美敦力公司最大的业务部门心脏节律疾病管理公司的总裁在美敦力之前，他曾担任西欧和Vice President血管Vice President和血管内业务部门总经理。在2002年加入美敦力之前，Mackin先生在Genzyme，Inc.工作了六年，担任心血管外科业务部的高级副总裁和总经理，并担任外科产品部的销售总监。在加入Genzyme之前，Mackin先生在Deknatel/Snowden-Pencer，Inc.担任了四年的各种职务，并在美国陆军担任了三年的中尉。Mackin先生在西北大学凯洛格管理研究生院（Northwestern University&8217；S Kellogg Graduate School of Management）获得工商管理硕士学位，并是西点军校（the U.S.Military Academy at West Point）的毕业生。
James P. Mackin assumed the position of President and Chief Executive Officer in September 2014 and was appointed to the Board of Directors in October 2014. Mr. Mackin has more than 20 years of experience in the medical device industry. Prior to joining CryoLife, Mr. Mackin served as President of Cardiac Rhythm Disease Management, the largest operating division of Medtronic, Inc. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002 Mr. Mackin worked for six years at Genzyme, Inc. serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr. Mackin spent four years at Deknatel/Snowden-Pencer, Inc. in various roles and three years as a First Lieutenant in the U.S. Army. Mr. Mackin received an MBA from Northwestern University’s Kellogg Graduate School of Management and is a graduate of the U.S. Military Academy at West Point.- JamesP.Mackin于2014年9月担任总裁兼首席执行官，并于2014年10月被任命为董事会成员。Mackin先生在医疗器械行业拥有超过20年的经验。在加入CryoLife公司之前，麦金先生曾担任美敦力公司最大的业务部门心脏节律疾病管理公司的总裁在美敦力之前，他曾担任西欧和Vice President血管Vice President和血管内业务部门总经理。在2002年加入美敦力之前，Mackin先生在Genzyme，Inc.工作了六年，担任心血管外科业务部的高级副总裁和总经理，并担任外科产品部的销售总监。在加入Genzyme之前，Mackin先生在Deknatel/Snowden-Pencer，Inc.担任了四年的各种职务，并在美国陆军担任了三年的中尉。Mackin先生在西北大学凯洛格管理研究生院（Northwestern University&8217；S Kellogg Graduate School of Management）获得工商管理硕士学位，并是西点军校（the U.S.Military Academy at West Point）的毕业生。
- James P. Mackin assumed the position of President and Chief Executive Officer in September 2014 and was appointed to the Board of Directors in October 2014. Mr. Mackin has more than 20 years of experience in the medical device industry. Prior to joining CryoLife, Mr. Mackin served as President of Cardiac Rhythm Disease Management, the largest operating division of Medtronic, Inc. At Medtronic, he previously held the positions of Vice President, Vascular, Western Europe and Vice President and General Manager, Endovascular Business Unit. Prior to joining Medtronic in 2002 Mr. Mackin worked for six years at Genzyme, Inc. serving as Senior Vice President and General Manager for the Cardiovascular Surgery Business Unit and as Director of Sales, Surgical Products division. Before joining Genzyme, Mr. Mackin spent four years at Deknatel/Snowden-Pencer, Inc. in various roles and three years as a First Lieutenant in the U.S. Army. Mr. Mackin received an MBA from Northwestern University’s Kellogg Graduate School of Management and is a graduate of the U.S. Military Academy at West Point.
- Jean F. Holloway
Jean F. Holloway，2012年加入Bard，担任副总裁、法律总顾问、秘书。加入Bard之前，她从2008年起在Medtronic, Inc.担任过多个执行职务，最后的是心脏和血管业务部副总裁、副法律总顾问。此前，她在Boston Scientific Corporation担任过多个执行职务，曾是Faegre & Benson LLP的合伙人。
Jean F. Holloway was appointed to the position of Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary in January 2016. She previoly served as Vice President, General Counsel, and Secretary beginning in April 2015 and was subsequently appointed to the additional position of Chief Compliance Officer in October 2015. Prior to joining Artivion, she held vario positions, including Vice President, General Counsel and Secretary of Bard, Deputy General Counsel, Medtronic, Inc., Vice President, Litigation, Boston Scientific, Inc., and Deputy General Counsel, Guidant Corporation. Ms. Holloway also spent nearly 15 years in private practice as a trial lawyer at Dorsey & Whitney, Faegre & Benson and Sidley & Atin. She clerked for two years on the Seventh Circuit Ct of Appeals for the Honorable Luther M. Swygert. Ms. Holloway has a JD/MBA from the University of Chicago and two undergraduate degrees from Yale University in engineering and political science.- Jean F. Holloway，2012年加入Bard，担任副总裁、法律总顾问、秘书。加入Bard之前，她从2008年起在Medtronic, Inc.担任过多个执行职务，最后的是心脏和血管业务部副总裁、副法律总顾问。此前，她在Boston Scientific Corporation担任过多个执行职务，曾是Faegre & Benson LLP的合伙人。
- Jean F. Holloway was appointed to the position of Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary in January 2016. She previoly served as Vice President, General Counsel, and Secretary beginning in April 2015 and was subsequently appointed to the additional position of Chief Compliance Officer in October 2015. Prior to joining Artivion, she held vario positions, including Vice President, General Counsel and Secretary of Bard, Deputy General Counsel, Medtronic, Inc., Vice President, Litigation, Boston Scientific, Inc., and Deputy General Counsel, Guidant Corporation. Ms. Holloway also spent nearly 15 years in private practice as a trial lawyer at Dorsey & Whitney, Faegre & Benson and Sidley & Atin. She clerked for two years on the Seventh Circuit Ct of Appeals for the Honorable Luther M. Swygert. Ms. Holloway has a JD/MBA from the University of Chicago and two undergraduate degrees from Yale University in engineering and political science.